6.7 C
New York
Friday, March 29, 2024

Vetr Upgrade’s REGN’s On Price Growth Following Positive Guidance

Courtesy of Benzinga.

The Vetr crowd upgraded its rating for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from 1 star (Strong Sell), issued three days ago, to 3 stars (Hold). Crowd sentiment at the time of the downgrade was edging cautious, with 55 percent of Vetr user ratings bearish.

May has been good to shares in the pharmaceutical company, which is up more than 17 percent over the first 18 days of the month. This is in part due to a successful earnings report, in addition to the company’s affirmation on positive guidance for 2017 that promised continued revenue growth.

Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd’s average target price for Regeneron is down at $437.82, which is still above the average analyst target price of $431.90. Less than 2 percent of Vetr users are holding REGN in their watch lists.

Latest Ratings for REGN

Date Firm Action From To
May 2017 Canaccord Genuity Upgrades Hold Buy
Mar 2017 UBS Initiates Coverage On Buy
Feb 2017 PiperJaffray Upgrades Neutral Overweight

View More Analyst Ratings for REGN


View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Health Care Price Target Crowdsourcing Analyst Ratings

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,450FansLike
396,312FollowersFollow
2,280SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x